Effect of imatinib mesylate combined with granulocyte colony-stimulating factor on leukaemic blast cells derived from advanced-stage chronic myelogenous leukaemia patients.
Neutropenia is a severe adverse effect that can occur when treating patients with imatinib mesylate for advanced-stage chronic myelogenous leukaemia (CML). Therefore, we evaluated in vitro the combined effect of imatinib and granulocyte colony-stimulating factor (G-CSF) on proliferation and apoptosis of Bcr-Abl-expressing leukaemic cells to infer the safety of G-CSF administration. In KU812 and K562 cell lines, G-CSF neither stimulated their proliferation nor abolished the suppressive effect of imatinib. However, it stimulated the proliferation of blast cells in 2 out of the 5 cases with advanced-stage CML. These in vitro studies appear to provide data for the decision of G-CSF administration in combination with imatinib in the treatment of neutropenic patients with advanced-stage CML.
Ota
Shuichi
S
Department of Internal Medicine, Gastroenterology and Hematology Section, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Musashi
Manabu
M
Kondo
Keiichi
K
Toyoshima
Nobuyasu
N
Toubai
Tomomi
T
Onozawa
Masahiro
M
Mori
Akio
A
Hashino
Satoshi
S
Tanaka
Junji
J
Matsuno
Kazuhiko
K
Imamura
Masahiro
M
Asaka
Masahiro
M
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects*; D001549:Benzamides; D001752:Blast Crisis / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects*; D004336:Drug Antagonism; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D064420:Drug-Related Side Effects and Adverse Reactions; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects; D016313:Genes, abl; D016179:Granulocyte Colony-Stimulating Factor / Q000037:antagonists & inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D000068877:Imatinib Mesylate; D020014:K562 Cells; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism; D010879:Piperazines / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000494:pharmacology* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D016179:Granulocyte Colony-Stimulating Factor; D000068877:Imatinib Mesylate